Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. 
Other Related Press Releases
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam